Evaxion Shares Latest EVX-01 Phase 2 Clinical Data In Webinar With Key Opinion Leader Adnan Khattak
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data In Webinar With Key Opinion Leader Adnan Khattak
Evaxion 在與主要意見領袖阿德南·哈塔克的網絡研討會上分享了最新的 EVX-01 第 2 期臨床數據
EVX-01 is Evaxion's lead clinical asset based upon its AI-Immunology platform and has recently published a phase 2 clinical update confirming former phase 1 results
Principal investigator Professor Adnan Khattak will walk us through this study's encouraging results and explain its potential for revolutionizing cancer treatment
EVX-01 是 Evaxion 基於其人工智能免疫學平台的主要臨床資產，最近發佈了 2 期臨床更新，證實了先前的 1 期結果
首席研究員阿德南·哈塔克教授將向我們介紹這項研究令人鼓舞的結果，並解釋其革新癌症治療的潛力
COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in the development of AI-Immunology powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study's Principal Investigator (PI), Professor Adnan Khattak. The webinar will take place...
丹麥哥本哈根，2023年11月6日（GLOBE NEWSWIRE）——專門開發人工智能免疫疫苗的臨床階段科...
登入免費觀看全文
登入/註冊